Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.
Becker
Richard C
RC
Alexander
John
J
Li
You Fu
YF
Bovill
Edwin
E
Spencer
Frederick A
FA
Robertson
Thomas L
TL
Kunitada
Satoshi
S
Dyke
Christopher K
CK
Harrington
Robert A
RA
D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology*; D001780:Blood Coagulation Tests; D002122:Calcium Chloride / Q000494:pharmacology; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004357:Drug Synergism; D017984:Enoxaparin / Q000494:pharmacology*; D015951:Factor Xa / Q000737:chemistry; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D006495:Heparin, Low-Molecular-Weight / Q000097:blood; D006801:Humans; D012680:Sensitivity and Specificity
D000925:Anticoagulants; D017984:Enoxaparin; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin; D015951:Factor Xa; D002122:Calcium Chloride; C095887:exatecan; D002166:Camptothecin